Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 6/20 | 0.49 |
| ▸ | SYK | P43405 | 3/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.41 |
| ▸ | F11 | P03951 | 1/20 | 0.40 |
| ▸ | TPSB2 | P20231 | 1/20 | 0.40 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21439692 | 0.94 | CFD (0.58) | CFDSYKIRAK4F11TPSB2 | |
| SCHEMBL21455330 | 0.88 | CFD (0.44) | CFDF11TPSB2SUCNR1MAPT | |
| SCHEMBL21439635 | 0.82 | CFD (0.72) | CFDSYKF11TPSB2SUCNR1 | |
| SCHEMBL21561816 | 0.80 | CFD (0.54) | CFDSYKIRAK4F11TPSB2 | |
| SCHEMBL21439700 | 0.78 | CFD (0.79) | CFDF11TPSB2SUCNR1 | |
| SCHEMBL21439710 | 0.74 | CFD (0.57) | CFDF11TPSB2SUCNR1 | |
| SCHEMBL21439533 | 0.73 | CFD (0.51) | CFDIRAK4SUCNR1MAPTMAPK1 | |
| SCHEMBL21438010 | 0.72 | CFD (0.58) | CFDF11TPSB2SUCNR1 | |
| SCHEMBL21455337 | 0.71 | BRD4 (0.48) | SYKMAPTSMN1; SMN2POLBALDH1A1 | |
| SCHEMBL25879458 | 0.70 | CFD (0.50) | CFDF11TPSB2SUCNR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | CFD 17/4885SYK 214/4885IRAK4 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.